|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 21, 2017 ) Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market
Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has had a worse overall survival than HER2-negative disease, which is considered less aggressive.
In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.
For more information about this report: http://www.reportsweb.com/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022
Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab) . These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.
In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment plan for the disease, poor affordability, and patients continuing to rely on the use of chemotherapies in the later lines of treatment. It is important for drug companies to consider the evolving reimbursement landscape when determining pricing strategies across the Southeast Asian markets, because this will significantly impact the uptake of premium drugs.
Scope
The current Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance.
- Which drugs are used as the standard treatment in each setting of the disease?
- What are the competitive advantages of the existing novel drugs?
- Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?
There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and molecular targets, including those that are well established in breast cancer, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
- Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59%, with the overall attrition rate for breast cancer standing at 85%.
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
The breast cancer Southeast Asian market will be valued at $2.7 billion in 2022, growing from $942.3m in 2015 at a CAGR of 16.2%.
- Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?
Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia, due to the emergence of novel therapies and the continued uptake of branded therapies.
- How will the annual cost of therapy and market size vary between the eight Southeast Asian markets?
- What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
- How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
- How will the potential launch of biosimilars influence each country?
- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
Various drivers and barriers will influence the market over the forecast period.
- What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001771862/sample
Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
- Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 11
2.1 Disease Introduction 11
2.2 Epidemiology 12
2.3 Symptoms 14
2.4 Etiology 15
2.5 Pathophysiology 16
2.6 Diagnosis 16
2.7 Prognosis and Disease Staging 18
2.8 Treatment Options 20
2.8.1 Surgery and Radiation Therapy 20
2.8.2 Chemotherapy 21
2.8.3 Hormonal Therapies 21
2.8.4 Targeted Therapies 22
2.9 Treatment Guidelines 23
3 Marketed Products 26
3.1 Overview 26
3.1.1 Herceptin (trastuzumab) - Genentech 27
3.1.2 Perjeta (pertuzumab) - Genentech 28
3.1.3 Afinitor (everolimus) - Novartis 29
3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate) - Novartis 30
3.1.5 Ibrance (palbociclib) - Pfizer 30
3.1.6 Ixempra (ixabepilone) - R-Pharm 31
3.1.7 Halaven (eribulin mesylate) - Eisai 32
3.1.8 Avastin (bevacizumab) - Genentech 32
3.1.9 Kadcyla (ado-trastuzumab emtansine) - Genentech 33
3.2 Comparative Efficacy and Safety of Marketed Products 34
4 Pipeline Analysis 40
4.1 Overview 40
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 40
4.2.1 Pipeline by Molecular Target 42
4.3 Promising Pipeline Molecules 43
4.3.1 Olaparib - AstraZeneca 43
4.3.2 Veliparib - AbbVie 44
4.3.3 Neratinib - Puma Biotechnology 46
4.3.4 Pembrolizumab - Merck & Co. 47
4.3.5 Ribociclib (Kisqali) - Novartis 48
4.3.6 Alpelisib - Novartis 50
4.3.7 Taselisib - Genentech 51
4.3.8 Vinflunine - Pierre-Fabre 54
4.3.9 Abemaciclib - Eli Lily 55
4.3.10 Niraparib - Tesaro 56
4.3.11 Buparlisib - Novartis 56
4.3.12 NeuVax (nelipepimut-S) - Galena Biopharma 57
4.3.13 Talazoparib - BioMarin 58
4.3.14 Atezolizumab - Roche 58
4.3.15 Entinostat - Syndax 59
4.3.16 Margetuximab - MacroGenics 60
4.3.17 OBI-822/821 - OBI Pharma 61
4.4 Comparative Efficacy and Safety of Pipeline Products 61
4.5 Product Competitiveness Framework 63
5 Clinical Trial Analysis 64
5.1 Failure Rate 64
5.1.1 Overall Failure Rate 64
5.1.2 Failure Rate by Phase and Molecule Type 65
5.1.3 Failure Rate by Phase and Molecule Target 66
5.2 Clinical Trial Duration 67
5.2.1 Clinical Trial Duration by Molecule Type 67
5.2.2 Clinical Trial Duration by Molecular Target 68
5.3 Clinical Trial Size 69
5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 69
5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 71
5.4 Competitive Clinical Trials Metrics Analysis 73
6 Multi-scenario Forecast 75
6.1 Geographical Markets 75
6.2 Southeast Asian Markets 75
6.3 South Korea 78
6.3.1 Treatment Usage Patterns 78
6.3.2 Annual Cost of Therapy 78
6.3.3 Market Size 80
6.4 Singapore 81
6.4.1 Treatment Usage Patterns 81
6.4.2 Annual Cost of Therapy 81
6.4.3 Market Size 82
6.5 Taiwan 83
6.5.1 Treatment Usage Patterns 83
6.5.2 Annual Cost of Therapy 84
6.5.3 Market Size 85
6.6 Malaysia 86
6.6.1 Treatment Usage Patterns 86
6.6.2 Annual Cost of Therapy 87
6.6.3 Market Size 88
6.7 Philippines 89
6.7.1 Treatment Usage Patterns 89
6.7.2 Annual Cost of Therapy 90
6.7.3 Market Size 91
6.8 Thailand 92
6.8.1 Treatment Usage Patterns 92
6.8.2 Annual Cost of Therapy 93
6.8.3 Market Size 94
6.9 Vietnam 95
6.9.1 Treatment Usage Patterns 95
6.9.2 Annual Cost of Therapy 96
6.9.3 Market Size 97
6.10 Indonesia 98
6.10.1 Treatment Usage Patterns 98
6.10.2 Annual Cost of Therapy 99
6.10.3 Market Size 100
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001771862/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
